Lakefront Biotherapeutics American Depositary Shares
LKFT
82 hedge funds and large institutions have $595M invested in Lakefront Biotherapeutics American Depositary Shares in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 15 closing their positions.
66% more call options, than puts
Call options by funds: $40.4M | Put options by funds: $24.3M
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
32% more capital invested
Capital invested by funds: $450M → $595M (+$145M)
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
3.42% more ownership
Funds ownership: 13.04% → 16.47% (+3.4%)
1% more funds holding
Funds holding: 81 → 82 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$34.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$33.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$15.7M |
| 4 |
6CM
683 Capital Management
New York
|
+$10.6M |
| 5 |
GC
Greenlight Capital
New York
|
+$9.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$12.8M |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$9.97M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.04M |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$3M |
| 5 |
Morgan Stanley
New York
|
-$2.14M |
LKFT Hedge Fund Activity: Q4 2021 in Review
82 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q4 2021, worth a combined $595M — up 32% from $450M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new LKFT positions and 15 closed out — a net gain of 4 holders — while 31 added to existing stakes and 23 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $34.7M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $12.8M sold.
- 82 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q4 2021, up from 81 in Q3 2021.
- Funds reported $595M of Lakefront Biotherapeutics American Depositary Shares stock for Q4 2021, up 32% quarter-over-quarter.
- 19 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q4 2021 and 15 closed out, a net change of +4 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q4 2021 was EcoR1 Capital, an estimated $34.7M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q4 2021 was Stonepine Capital Management, an estimated $12.8M sold.
Based on aggregated 13F filings for Q4 2021.